Trial reportDiabetologia2004
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
Trial report in Diabetologia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00095654 (The DREAM), which is not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.The Cochrane database of systematic reviews · 2024Pooled it
- Early effective intervention can significantly reduce all-cause mortality in prediabetic patients: a systematic review and meta-analysis based on high-quality clinical studies.Frontiers in endocrinology · 2024Pooled it
- Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies.The American journal of clinical nutrition · 2018Pooled it
- The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression.Molecular psychiatry · 2013Pooled it
- Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.Journal of diabetes research · 2017Trial
- Incidence of diabetes following ramipril or rosiglitazone withdrawal.Diabetes care · 2011Trial
- Trial
- First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular diabetology · 2008Trial
- Urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol is positively associated with tooth loss.BMC public health · 2025Article
- Observational
- Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study.Scientific reports · 2017Article
- Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology.Scientific reports · 2016Article
- Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study.Scientific reports · 2016Article
- Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population.Translational psychiatry · 2015Article
- Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.PPAR research · 2015Review
- Modulation of hypovitaminosis D-induced islet dysfunction and insulin resistance through direct suppression of the pancreatic islet renin-angiotensin system in mice.Diabetologia · 2013Article
- Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology · 2012Article
- Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes.Diabetologia · 2010Article
- Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis.Endocrine · 2010Article
- Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?International journal of diabetes in developing countries · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisDiabetes is a rapidly rising independent risk factor for atherosclerosis and serious illness. This risk can be reduced by lifestyle changes and/or various drugs. Novel therapies to prevent diabetes, as well as new risk factors for diabetes, atherosclerosis and obesity require testing and identification.
methodsPeople with impaired fasting glucose or impaired glucose tolerance were randomised to ramipril (15 mg/day) or placebo and rosiglitazone (8 mg/day) or placebo with a 2x2 factorial design. They are assessed semi-annually for the primary outcome (diabetes or death). Diabetes is diagnosed if two consecutive plasma glucose levels exceed diagnostic thresholds (i.e. fasting >/=7.0 mmol/l or 2-h >/=11.1 mmol/l) within a 3-month period. Assuming an annual primary outcome incidence of 5%, there is more than 90% power to detect a 22% reduction. Approximately 20% of participants are having annual carotid ultrasounds to assess the effects on atherosclerosis. Patients screened but not randomised are being followed prospectively to identify determinants of obesity, diabetes and related disorders.
resultsA total of 24,872 individuals in 21 countries were screened over 2 years and are eligible for follow-up. Of these, 5269 were randomised: 1835 (35%) had isolated impaired glucose tolerance, 739 (14%) had isolated impaired fasting glucose, and 2692 (51%) had both disorders. Annual carotid ultrasounds are currently being performed in 1406 randomised individuals. CONCLUSIONS/
interpretationThe DREAM trial and related studies will determine if ramipril or rosiglitazone reduces the number of cases of diabetes and atherosclerosis, and will identify novel risk factors for diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.